کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5719126 1607413 2017 13 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Original ArticlesDexamethasone for Parapneumonic Pleural Effusion: A Randomized, Double-Blind, Clinical Trial
ترجمه فارسی عنوان
مقالات اصلی دگزامتازون برای عفونت پارالمپومونیک پلورال: یک آزمایش تصادفی، دوبار کلیک، آزمایش بالینی
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی پریناتولوژی (پزشکی مادر و جنین)، طب اطفال و بهداشت کودک
چکیده انگلیسی

ObjectiveTo assess whether dexamethasone (DXM) decreases the time to recovery in patients with parapneumonic pleural effusion.Study designThis was a multicenter, randomized, double blind, parallel-group, placebo-controlled clinical trial of 60 children, ranging in age from 1 month to 14 years, with community-acquired pneumonia (CAP) and pleural effusion. Patients received either intravenous DXM (0.25 mg/kg/dose) or placebo every 6 hours over a period of 48 hours, along with antibiotics. The primary endpoint was the time to recovery in hours, defined objectively. We also evaluated complications and adverse events.ResultsAmong the 60 randomized patients (mean age, 4.7 years; 58% female), 57 (95%) completed the study. Compared with placebo recipients, the patients receiving DXM had a shorter time to recovery, after adjustment by severity group and stratification by center (hazard ratio, 1.95; 95% CI, 1.10-3.45; P = .021). The median time to recovery for patients receiving DXM was 68 hours (2.8 days) shorter than patients receiving placebo (109 hours vs 177 hours; P = .037). In exploratory subgroup analysis, the median time to recovery for patients with simple effusion receiving DXM was 76 hours (3.1 days) shorter than for patients with simple effusion receiving placebo (P = .017). The median time to recovery for patients with complicated effusion receiving DXM was 14 hours (0.5 days) shorter than for patients with complicated effusion receiving placebo (P = .66). The difference in the effect of DXM in the 2 severity groups was not statistically significant (P = .138 for interaction). There were no significant differences in complications or adverse events attributable to the study drugs, except for hyperglycemia.ConclusionIn this trial, DXM seemed to be a safe and effective adjunctive therapy for parapneumonic pleural effusion.Trial registrationClinicalTrials.gov: NCT01261546.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: The Journal of Pediatrics - Volume 185, June 2017, Pages 117-123.e6
نویسندگان
, , , , , , , , , , , , , ,